Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

Compare

4,058 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SRPT Analyst Ratings

Hold

6 Buy

10 Hold

4 Sell

Based on 20 analysts giving stock ratings to

Sarepta

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SRPT Stock 12 Month Forecast

Average Price Target

$21.29

▲(29.82% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Sarepta Therapeutics in the last 3 months. The average price target is $21.29 with a high forecast of $38.00 and a low forecast of $5.00. The average price target represents a 29.82% change from the last price of $16.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","107":"$107","29.75":"$29.8","55.5":"$55.5","81.25":"$81.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,29.75,55.5,81.25,107],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.32,17.987692307692306,19.655384615384616,21.323076923076922,22.99076923076923,24.658461538461538,26.326153846153844,27.993846153846153,29.661538461538463,31.32923076923077,32.996923076923075,34.66461538461539,36.332307692307694,{"y":38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.32,16.70230769230769,17.084615384615386,17.466923076923077,17.84923076923077,18.231538461538463,18.613846153846154,18.996153846153845,19.378461538461536,19.76076923076923,20.143076923076922,20.525384615384617,20.907692307692308,{"y":21.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.32,15.44923076923077,14.57846153846154,13.707692307692309,12.836923076923078,11.966153846153848,11.095384615384615,10.224615384615385,9.353846153846154,8.483076923076924,7.612307692307693,6.741538461538463,5.8707692307692305,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":106.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.78,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.74,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 67, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 81, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 27</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.16,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 69, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 26</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19.32,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":24.01,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":19.72,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":21.52,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 14</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":20.72,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.32,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$38.00

Average Price Target$21.29

Lowest Price Target$5.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yun Zhong

Wedbush

$16.4→$29

Buy

76.83%

Upside

Reiterated

03/15/26

Analysts' Top Healthcare Picks: Edgewise Therapeutics (EWTX), Sarepta Therapeutics (SRPT)

Uy Ear

Mizuho Securities

$26→$31

Buy

89.02%

Upside

Reiterated

03/12/26

Mizuho Securities Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)

Biren Amin

Piper Sandler

$16

Hold

-2.44%

Downside

Reiterated

03/11/26

Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (NASDAQ: MLTX), Sarepta Therapeutics (NASDAQ: SRPT) and vTv Therapeutics (NASDAQ: VTVT)

Yigal Nochomovitz

Citi

$8→$9

Sell

-45.12%

Downside

Reiterated

03/10/26

Sarepta price target raised to $9 from $8 at CitiSarepta price target raised to $9 from $8 at Citi

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$19

Buy

15.85%

Upside

Reiterated

03/09/26

Guggenheim Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)

Anupam Rama

J.P. Morgan

―

Hold

―

Reiterated

03/03/26

Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL), Intellia Therapeutics (NASDAQ: NTLA) and Sarepta Therapeutics (NASDAQ: SRPT)

Gavin Clark-Gartner

Evercore ISI

$17

Hold

3.66%

Upside

Reiterated

03/02/26

Sarepta Therapeutics (SRPT) Gets a Hold from Evercore ISI

Mitchell Kapoor

H.C. Wainwright

Sell

-69.51%

Downside

Reiterated

03/02/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Mineralys Therapeutics, Inc. (NASDAQ: MLYS), Exelixis (NASDAQ: EXEL) and Sarepta Therapeutics (NASDAQ: SRPT)

Yanan Zhu

Wells Fargo

$45→$38

Buy

131.71%

Upside

Reiterated

02/27/26

Sarepta price target lowered to $38 from $45 at Wells FargoSarepta price target lowered to $38 from $45 at Wells Fargo

Eliana Merle

Barclays

$20

Hold

21.95%

Upside

Reiterated

02/27/26

Barclays Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)

Sami Corwin

William Blair

―

Hold

―

Reiterated

02/26/26

Maintaining Hold on Sarepta: Weaker Elevidys Outlook, Competitive PMO Pressures, and CEO Transition Temper Near‑Term Upside

Andreas Argyrides

Oppenheimer

$37

Buy

125.61%

Upside

Reiterated

02/26/26

Sarepta Therapeutics (SRPT) Gets a Buy from Oppenheimer

Gil Blum

Needham

―

Sell

―

Reiterated

02/26/26

Cut Guidance, Clinical Uncertainty, and PMO Franchise Risk Underscore Negative Risk–Reward for Sarepta

Michael Ulz

Morgan Stanley

$20

Hold

21.95%

Upside

Reiterated

02/26/26

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (NASDAQ: SRPT) and ACADIA Pharmaceuticals (NASDAQ: ACAD)

Brian Skorney

Robert W. Baird

$22→$20

Hold

21.95%

Upside

Reiterated

02/26/26

Sarepta price target lowered to $20 from $22 at BairdSarepta price target lowered to $20 from $22 at Baird

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yun Zhong

Wedbush

$16.4→$29

Buy

76.83%

Upside

Reiterated

03/15/26

Analysts' Top Healthcare Picks: Edgewise Therapeutics (EWTX), Sarepta Therapeutics (SRPT)

Uy Ear

Mizuho Securities

$26→$31

Buy

89.02%

Upside

Reiterated

03/12/26

Mizuho Securities Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)

Biren Amin

Piper Sandler

$16

Hold

-2.44%

Downside

Reiterated

03/11/26

Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (NASDAQ: MLTX), Sarepta Therapeutics (NASDAQ: SRPT) and vTv Therapeutics (NASDAQ: VTVT)

Yigal Nochomovitz

Citi

$8→$9

Sell

-45.12%

Downside

Reiterated

03/10/26

Sarepta price target raised to $9 from $8 at CitiSarepta price target raised to $9 from $8 at Citi

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$19

Buy

15.85%

Upside

Reiterated

03/09/26

Guggenheim Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)

Anupam Rama

J.P. Morgan

―

Hold

―

Reiterated

03/03/26

Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL), Intellia Therapeutics (NASDAQ: NTLA) and Sarepta Therapeutics (NASDAQ: SRPT)

Gavin Clark-Gartner

Evercore ISI

$17

Hold

3.66%

Upside

Reiterated

03/02/26

Sarepta Therapeutics (SRPT) Gets a Hold from Evercore ISI

Mitchell Kapoor

H.C. Wainwright

Sell

-69.51%

Downside

Reiterated

03/02/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Mineralys Therapeutics, Inc. (NASDAQ: MLYS), Exelixis (NASDAQ: EXEL) and Sarepta Therapeutics (NASDAQ: SRPT)

Yanan Zhu

Wells Fargo

$45→$38

Buy

131.71%

Upside

Reiterated

02/27/26

Sarepta price target lowered to $38 from $45 at Wells FargoSarepta price target lowered to $38 from $45 at Wells Fargo

Eliana Merle

Barclays

$20

Hold

21.95%

Upside

Reiterated

02/27/26

Barclays Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)

Sami Corwin

William Blair

―

Hold

―

Reiterated

02/26/26

Maintaining Hold on Sarepta: Weaker Elevidys Outlook, Competitive PMO Pressures, and CEO Transition Temper Near‑Term Upside

Andreas Argyrides

Oppenheimer

$37

Buy

125.61%

Upside

Reiterated

02/26/26

Sarepta Therapeutics (SRPT) Gets a Buy from Oppenheimer

Gil Blum

Needham

―

Sell

―

Reiterated

02/26/26

Cut Guidance, Clinical Uncertainty, and PMO Franchise Risk Underscore Negative Risk–Reward for Sarepta

Michael Ulz

Morgan Stanley

$20

Hold

21.95%

Upside

Reiterated

02/26/26

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (NASDAQ: SRPT) and ACADIA Pharmaceuticals (NASDAQ: ACAD)

Brian Skorney

Robert W. Baird

$22→$20

Hold

21.95%

Upside

Reiterated

02/26/26

Sarepta price target lowered to $20 from $22 at BairdSarepta price target lowered to $20 from $22 at Baird

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sarepta Therapeutics

3 Months

xxx

Success Rate

22/38 ratings generated profit

Average Return

+7.42%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +7.42% per trade.

1 Year

Yun ZhongWedbush

Success Rate

14/21 ratings generated profit

Average Return

+12.04%

a rating ―

Copying Yun Zhong's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +12.04% per trade.

2 Years

xxx

Success Rate

10/21 ratings generated profit

Average Return

+8.91%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 47.62% of your transactions generating a profit, with an average return of +8.91% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SRPT Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SRPT has received 13 Buy Ratings, 25 Hold Ratings, and 12 Sell Ratings. SRPT average Analyst price target in the past 3 months is 21.29.

Each month's total comprises the sum of three months' worth of ratings.

SRPT Financial Forecast

SRPT Earnings Forecast

Next quarter’s earnings estimate for SRPT is $1.13 with a range of -$0.76 to $2.85. The previous quarter’s EPS was -$3.93. SRPT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year SRPT has Performed in-line its overall industry.

SRPT Sales Forecast

Next quarter’s sales forecast for SRPT is $479.56M with a range of $310.20M to $727.92M. The previous quarter’s sales results were $442.93M. SRPT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year SRPT has Performed in-line its overall industry.

SRPT Stock Forecast FAQ

What is SRPT’s average 12-month price target, according to analysts?

Based on analyst ratings, Sarepta Therapeutics’s 12-month average price target is 21.29.

What is SRPT’s upside potential, based on the analysts’ average price target?

Sarepta Therapeutics has 29.82% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SRPT a Buy, Sell or Hold?

Sarepta Therapeutics has a consensus rating of Hold which is based on 6 buy ratings, 10 hold ratings and 4 sell ratings.

What is Sarepta Therapeutics’s price target?

The average price target for Sarepta Therapeutics is 21.29. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $38.00 ,the lowest forecast is $5.00. The average price target represents 29.82% Increase from the current price of $16.4.

What do analysts say about Sarepta Therapeutics?

Sarepta Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of SRPT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

SRPT Analyst Ratings

SRPT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sarepta Therapeutics

SRPT Analyst Recommendation Trends

SRPT Financial Forecast

SRPT Earnings Forecast

SRPT Sales Forecast

SRPT Stock Forecast FAQ

Detailed List of Analyst Forecasts